Zhengye Biotechnology Holding Limited (ZYBT) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Zhengye Biotechnology Holding Limited stock $0.20, price $1.52, that is 86.8% below the price, quality 35 out of 100. Rating: strongly overvalued. Calculated from audited financials with 5 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
22‑month range $0.6460 – $14.15 · fair‑value band $0.1900 – $0.2100 · the $1.52 price screens above the $0.2000 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Zhengye Biotechnology Holding Limited Ordinary Shares in your weekly email
Every Wednesday you see whether Zhengye Biotechnology Holding Limited Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China.
Show moreShow less
The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs.
In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China.
Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Stock analysis
Zhengye Biotechnology Holding Limited (ZYBT) currently trades at $1.52, while our model-based Fair Value estimate is $0.2000, 87% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $0.4100 per share, and 0 of the 5 models we run sit above the $1.52 price.
Bear case: the DCF Models group reads lowest at $0.2000, and 5 of the 5 models stay below the price. Data coverage for this calculation is low.
Scenario range: $0.1900 (bear) to $0.2100 (bull), the price of $1.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Zhengye Biotechnology Holding Limited Ordinary Shares reported revenue of 116M CNY in FY2025 versus 214M CNY in FY2021, a compound −14.1%/yr. Reported net income was −69.8M CNY in FY2025.
Key figures
Market cap $72.0M Micro · P/S ratio 0.59 · EPS (TTM) $−0.2000 · Net margin −60.0% · Return on equity −25.2% · Return on assets (EBIT) 4.3% (5-year average) · Operating margin −77.0% · Revenue (TTM) 116M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 81% below its 52-week high and 135% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −87%, ZYBT screens richer than that median.
Fair Value models
Bear$0.1900Fair Value $0.2000Bull$0.2100
Price $1.52 · Downside -86.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−37.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−23.5%
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
24.5% (2021) → −58.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
more than +80 %
Yearly growth needed for the next five years to justify today's price.
Compare Zhengye Biotechnology Holding Limited Ordinary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score35 · Bottom 25%
Fair Value upside−86.8% · Bottom 25%
Profitability
Return on assets−16.0% · Bottom 25%
Net margin (12 months)−60.0% · Bottom 25%
Operating margin (12 months)−77.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)−40.9% · Bottom 25%
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.92× · Pricier than median
P/S (12 months)4.13× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)0· sector 25
PAST (return on equity)0· sector 25
HEALTH (low debt)98· sector 96
DIVIDEND (yield)0· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Zhengye Biotechnology Holding Limited (ZYBT) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $0.2000 versus a price of $1.52, about 87% lower (overvalued).
What is the fair value of ZYBT?
Our model-based fair value for Zhengye Biotechnology Holding Limited is $0.2000 (as of Nov 9, 2026), built from audited fundamentals. The current price: $1.52.
What is the quality score of ZYBT?
Zhengye Biotechnology Holding Limited has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhengye Biotechnology Holding Limited (ZYBT)?
Our model-based price target is the fair value of $0.2000 (as of Nov 9, 2026) from 5 valuation models. Cautious scenario $0.1900, optimistic scenario $0.2100. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhengye Biotechnology Holding Limited Ordinary Shares stock forecast for 2026?
Our models put fair value at $0.2000, about 87% lower versus a price of $1.52 (overvalued). Cautious scenario $0.1900, optimistic scenario $0.2100. The calculation is refreshed regularly with new filings.
What is the revenue of Zhengye Biotechnology Holding Limited (ZYBT)?
Zhengye Biotechnology Holding Limited reported trailing-twelve-month revenue of about 116M CNY (latest available figure, as of Nov 9, 2026).
Does Zhengye Biotechnology Holding Limited Ordinary Shares pay a dividend?
Zhengye Biotechnology Holding Limited does not currently pay a dividend.
What growth is priced into Zhengye Biotechnology Holding Limited (ZYBT)?
For today's price to be fair in a discounted-cash-flow model, Zhengye Biotechnology Holding Limited would have to grow free cash flow by more than 80 % per year for five years (discount rate 12.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -14.1 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of ZYBT use?
Our models discount Zhengye Biotechnology Holding Limited at 12.7 %: a base by market capitalisation (micro), country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zhengye Biotechnology Holding Limited that is more than 80 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.7 %) and the same formula as our fair value.
How much growth has Zhengye Biotechnology Holding Limited (ZYBT) delivered so far?
Over the past 4 years revenue at Zhengye Biotechnology Holding Limited grew -14.1 % a year. The price currently implies free-cash-flow growth of more than 80 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zhengye Biotechnology Holding Limited (ZYBT) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Zhengye Biotechnology Holding Limited (more than 80 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zhengye Biotechnology Holding Limited (ZYBT)?
The free-cash-flow yield on the price is 0.15 %: that much free cash flow Zhengye Biotechnology Holding Limited produces per unit of market value. When it exceeds the discount rate of our models (12.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zhengye Biotechnology Holding Limited (ZYBT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhengye Biotechnology Holding Limited it is $0.2000 per share (as of Nov 9, 2026), against a price of $1.52. It is the blended result of 5 valuation models in 3 families (DCF Models, Asset-Based, Growth DCF).
Is Zhengye Biotechnology Holding Limited Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 9, 2026, ZYBT trades above its calculated fair value: price $1.52, fair value $0.2000, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZYBT?
No. The price is what the market pays today ($1.52); the fair value is what the company's own numbers justify ($0.2000). For Zhengye Biotechnology Holding Limited the two are $1.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhengye Biotechnology Holding Limited Ordinary Shares worth?
The market values Zhengye Biotechnology Holding Limited at about $72.0M (market capitalisation, as of Nov 9, 2026). Per share that is $1.52; our models calculate a fair value of $0.2000 per share.
What do the bullish and bearish scenarios say about ZYBT?
Our models span a range for Zhengye Biotechnology Holding Limited: cautious scenario $0.1900, base $0.2000, optimistic $0.2100 per share (as of Nov 9, 2026, price $1.52). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Zhengye Biotechnology Holding Limited (ZYBT)?
Balance-sheet figures for Zhengye Biotechnology Holding Limited (as of Nov 9, 2026): return on equity −25.2%, debt of 0.04 per unit of equity. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is ZYBT from its 52-week high?
Zhengye Biotechnology Holding Limited trades at $1.52, about 81% below its 52-week high of $8.01 and 135% above the low of $0.6460 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of $0.2000 is for.
Which stocks are comparable to Zhengye Biotechnology Holding Limited Ordinary Shares?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhengye Biotechnology Holding Limited Ordinary Shares stock attractive at the current price?
The data as of Nov 9, 2026: price $1.52, calculated fair value $0.2000 (−87%), Quality Score 35/100, from 5 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZYBT calculated?
We run Zhengye Biotechnology Holding Limited through 5 models from 3 families: DCF Models, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $0.2000 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Zhengye Biotechnology Holding Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhengye Biotechnology Holding Limited (ZYBT)?
The closing price on Nov 11, 2026 was $1.52. Our model-based fair value is $0.2000, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhengye Biotechnology Holding Limited Ordinary Shares right now?
The price sits above even our optimistic bull case ($0.2100). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band ($0.1900 to $0.2100), unusually little disagreement for a valuation.
Key figures of Zhengye Biotechnology Holding Limited
How large is the market capitalisation of Zhengye Biotechnology Holding Limited (ZYBT)?
The market capitalisation of Zhengye Biotechnology Holding Limited is $72.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhengye Biotechnology Holding Limited (ZYBT)?
The price-to-sales ratio of Zhengye Biotechnology Holding Limited is 0.59 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhengye Biotechnology Holding Limited (ZYBT)?
Earnings per share at Zhengye Biotechnology Holding Limited are $−0.2000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Zhengye Biotechnology Holding Limited (ZYBT)?
The net margin of Zhengye Biotechnology Holding Limited is −60.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhengye Biotechnology Holding Limited (ZYBT)?
The return on equity (ROE) of Zhengye Biotechnology Holding Limited is −25.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhengye Biotechnology Holding Limited (ZYBT)?
On an EBIT basis the return on assets of Zhengye Biotechnology Holding Limited is 4.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhengye Biotechnology Holding Limited (ZYBT)?
The operating margin of Zhengye Biotechnology Holding Limited is −77.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhengye Biotechnology Holding Limited (ZYBT)?
Revenue at Zhengye Biotechnology Holding Limited is growing −40.9% versus a year earlier (3y avg −23.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhengye Biotechnology Holding Limited (ZYBT)?
Earnings per share at Zhengye Biotechnology Holding Limited are growing −79.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Zhengye Biotechnology Holding Limited (ZYBT) carry?
The net debt of Zhengye Biotechnology Holding Limited is 24.8M CNY (fiscal year 2025, ≈ 35.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhengye Biotechnology Holding Limited Ordinary Shares in the live analysis
One click puts Zhengye Biotechnology Holding Limited Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026